Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 known ✓ | O15379 | 2/20 | 0.63 |
| ▸ | HDAC4 known ✓ | P56524 | 2/20 | 0.63 |
| ▸ | HDAC1 known ✓ | Q13547 | 2/20 | 0.63 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 2/20 | 0.63 |
| ▸ | HDAC2 known ✓ | Q92769 | 2/20 | 0.63 |
| ▸ | HDAC10 known ✓ | Q969S8 | 2/20 | 0.63 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 2/20 | 0.63 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 2/20 | 0.63 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 2/20 | 0.63 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 2/20 | 0.63 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 2/20 | 0.63 |
| ▸ | CA2 known ✓ | P00918 | 4/20 | 0.59 |
| ▸ | PARP1 known ✓ | P09874 | 1/20 | 0.59 |
| ▸ | PDE4B known ✓ | Q07343 | 1/20 | 0.56 |
| ▸ | MMP1 known ✓ | P03956 | 1/20 | 0.54 |
| ▸ | GSK3B | P49841 | 1/20 | 0.63 |
| ▸ | CA1 | P00915 | 4/20 | 0.59 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.59 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.59 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL182867 | 0.98 | HDAC3 (0.66) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL29291728 | 0.92 | HDAC3 (0.59) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL13238323 | 0.85 | SMN1; SMN2 (0.69) | PARP10MAPTNPC1RAB9AALDH1A1 | |
| Hydrochloric Acid SCHEMBL13738814 | 0.82 | GSK3B (0.42) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL10789249 | 0.82 | NPC1 (0.67) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL2603411 | 0.82 | CYP1A2 (0.67) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL883105 | 0.81 | PARP10 (0.58) | PARP10PARP2PARP4MAPTRAB9A | |
| SCHEMBL153386 | 0.81 | ALDH1A1 (0.76) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL16552644 | 0.81 | MMP1 (0.76) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Hydrochloric Acid SCHEMBL3848968 | 0.81 | CA1 (0.65) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140134283-A1 | Compositions and Methods for Affecting Mental State and Body Composition | USPlabs. LLC (US) | 2014-05-15 | — | — | US | claimed |
| EP-0877298-B1 | Coated xerographic photographic paper | XEROX CORP (US) | 2001-08-29 | — | — | EP | claimed |
| US-5908723-A | Recording sheets | XEROX CORPORATION (US) | 1999-06-01 | — | — | US | claimed |
| US-5846637-A | Coated xerographic photographic paper | XEROX CORPORATION (US) | 1998-12-08 | — | — | US | claimed |
| EP-0877298-A2 | Coated xerographic photographic paper | Xerox Corporation (US) | 1998-11-11 | — | — | EP | claimed |
| WO-2025059259-A1 | NEW PROCESS FOR PHENYLEPHRINE AND SALBUTAMOL AND RELATED COMPOUNDS VIA ASYMETRIC TRANSFER HYDROGENATION OF UNPROTECTED AMINO KETONES | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2025-03-20 | — | — | WO | disclosed |
| CN-115819366-B | Preparation method of 2-aroyl substituted oxazole compound and compound prepared by same | 重庆医科大学 | 2024-05-24 | — | — | CN | disclosed |
| US-20230296514-A1 | Zinc-Selective Fluorescent Probes for Emission-Ratiometric Imaging | GEORGIA TECH RESEARCH CORPORATION | 2023-09-21 | — | — | US | disclosed |
| CN-111606888-B | Pyrrole derivative and preparation method and application thereof | 中国药科大学 | 2023-08-18 | — | — | CN | disclosed |
| CN-115819366-A | Preparation method of 2-aroyl substituted oxazole compound and compound prepared by same | 重庆医科大学 | 2023-03-21 | — | — | CN | disclosed |
| US-11604141-B2 | Zinc-selective fluorescent probes for emission-ratiometric imaging | GEORGIA TECH RESEARCH CORPORATION (US) | 2023-03-14 | — | — | US | disclosed |
| CN-109180515-B | Synthetic method of N- [ 2-hydroxy-2- (4-methoxyphenyl) ethyl ] cinnamamide | 苏利制药科技江阴有限公司 | 2021-04-06 | — | — | CN | disclosed |
| EP-0499222-A1 | Liquid crystal composition, liquid crystal device, display apparatus and display method | CANON KABUSHIKI KAISHA (JP) | 1992-08-19 | — | — | EP | disclosed |
| EP-0476567-A1 | Mesomorphic compound, liquid crystal composition, liquid crystal device, display apparatus and display method | CANON KABUSHIKI KAISHA (JP) | 1992-03-25 | — | — | EP | disclosed |
| EP-0460624-A2 | Liquid crystal composition, liquid crystal device, display apparatus and display method | CANON KABUSHIKI KAISHA (JP) | 1991-12-11 | — | — | EP | disclosed |
| EP-0439170-A2 | Mesomorphic compound, liquid crystal composition containing same, liquid crystal device using same and display apparatus | CANON KABUSHIKI KAISHA (JP) | 1991-07-31 | — | — | EP | disclosed |
| EP-0238357-B1 | 1,2,4-TRIAZINONE DERIVATIVES, THEIR PREPARATION AND USE | Sankyo Company Limited (JP) | 1991-05-29 | — | — | EP | disclosed |
| US-4898862-A | 1,2,4-triazinone derivatives, their preparation and use | SANKYO COMPANY LIMITED (JP) | 1990-02-06 | — | — | US | disclosed |
| EP-0238357-A2 | 1,2,4-Triazinone derivatives, their preparation and use | Sankyo Company Limited (JP) | 1987-09-23 | — | — | EP | disclosed |
| US-4506368-A | PHOTOSTABILITY | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 1985-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140134283-A1 | Compositions and Methods for Affecting Mental State and Body Composition | SHBG, PYGM, PYGB | HDAC3 3322/4885HDAC4 3023/4885HDAC1 2506/4885 |
| US-20230296514-A1 | Zinc-Selective Fluorescent Probes for Emission-Ratiometric Imaging | ZRANB2, ZFR, SLC30A6 | HDAC3 621/4885HDAC4 2137/4885HDAC1 675/4885 |
| US-11604141-B2 | Zinc-selective fluorescent probes for emission-ratiometric imaging | ZRANB2, ZFR, SLC30A6 | HDAC3 621/4885HDAC4 2137/4885HDAC1 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.